NCT04466917 - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | Biotech Hunter

Timeline

Start Date

May 15, 2021

Primary Completion Date

November 13, 2022

Study Completion Date

November 13, 2022

Conditions

Metastatic Non-small Cell Lung Cancer (NSCLC)Non-squamous NSCLC

Interventions

DRUG

ABP 215

ABP 215 will be administered at a dose of 15 mg/kg IV

DRUG

Bevacizumab

Bevacizumab will be administered at a dose of 15 mg/kg IV

DRUG

Paclitaxel

Paclitaxel will be administered 175 mg/m2 IV

DRUG

Carboplatin

Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV